AR046379A1 - Una molecula de enlace de mcp-1 humana, un proceso para dicha produccion, construcciones de adn, un vector de expresion, composiciones farmaceuticas y el uso de dicha molecula de enlace de mcp-1 para la preparacion de un medicamento - Google Patents
Una molecula de enlace de mcp-1 humana, un proceso para dicha produccion, construcciones de adn, un vector de expresion, composiciones farmaceuticas y el uso de dicha molecula de enlace de mcp-1 para la preparacion de un medicamentoInfo
- Publication number
- AR046379A1 AR046379A1 ARP010103086A ARP010103086A AR046379A1 AR 046379 A1 AR046379 A1 AR 046379A1 AR P010103086 A ARP010103086 A AR P010103086A AR P010103086 A ARP010103086 A AR P010103086A AR 046379 A1 AR046379 A1 AR 046379A1
- Authority
- AR
- Argentina
- Prior art keywords
- mcp
- molecula
- link
- gly
- asp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Una molécula de enlace de MCP-1, la cual comprende un sitio de enlace de antígeno que comprende al menos un dominio variable de cadena pesada de inmunoglobulina (VH) en secuencia, las regiones hipervariables CDR1, CDR2, y CDR3, dicha CDR1 tiene la secuencia de aminoácidos His-Tyr-Trp-Met-Ser, teniendo la CDR2 la secuencia de aminoácidos Asn-lle-Glu-Gln-Asp-Gly-Ser-Glu-Lys-Tyr-Tyr-Val-Asp-Ser-Val-Lys-Gly, y dicha CDR3 tiene la secuencia de aminoácidos Asp-Leu-Glu-Gly-Leu-His-Gly-Asp-Gly-Tyr- Phe-Asp-Leu; y sus equivalentes directos, un proceso para dicha producción, construcciones de ADN, un vector de expresión para la expresión de una molécula de enlace de MCP-1, composiciones farmacéuticas y uso de una molécula de enlace de MCP-1, que reacciona cruzadamente con eotaxina y que es capaz de inhibir el enlace de MCP-1 y eotaxina a sus receptores , para la preparación de un medicamento para el tratamiento de una enfermedad o desorden mediado por MCP-1 o eotaxina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0016138.0A GB0016138D0 (en) | 2000-06-30 | 2000-06-30 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046379A1 true AR046379A1 (es) | 2005-12-07 |
Family
ID=9894801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010103086A AR046379A1 (es) | 2000-06-30 | 2001-06-28 | Una molecula de enlace de mcp-1 humana, un proceso para dicha produccion, construcciones de adn, un vector de expresion, composiciones farmaceuticas y el uso de dicha molecula de enlace de mcp-1 para la preparacion de un medicamento |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20040047860A1 (es) |
| EP (1) | EP1299421B1 (es) |
| JP (2) | JP3920215B2 (es) |
| KR (1) | KR100603899B1 (es) |
| CN (1) | CN100486996C (es) |
| AR (1) | AR046379A1 (es) |
| AT (1) | ATE426616T1 (es) |
| AU (2) | AU8390301A (es) |
| BR (1) | BR0112086A (es) |
| CA (1) | CA2412775A1 (es) |
| CZ (1) | CZ20024256A3 (es) |
| DE (1) | DE60138102D1 (es) |
| EC (1) | ECSP024402A (es) |
| ES (1) | ES2322643T3 (es) |
| GB (1) | GB0016138D0 (es) |
| HU (1) | HUP0301477A3 (es) |
| IL (1) | IL153721A0 (es) |
| MX (1) | MXPA03000201A (es) |
| NO (1) | NO20026063L (es) |
| NZ (1) | NZ523195A (es) |
| PE (1) | PE20020125A1 (es) |
| PL (1) | PL207133B1 (es) |
| PT (1) | PT1299421E (es) |
| RU (1) | RU2314316C2 (es) |
| SK (1) | SK18122002A3 (es) |
| WO (1) | WO2002002640A2 (es) |
| ZA (1) | ZA200300199B (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001066754A1 (en) | 2000-03-03 | 2001-09-13 | Cambridge Antibody Technology Limited | Human antibodies against eotaxin and their use |
| US6946546B2 (en) | 2000-03-06 | 2005-09-20 | Cambridge Antibody Technology Limited | Human antibodies against eotaxin |
| AU2002357770B2 (en) | 2001-11-30 | 2008-07-31 | Biogen Ma Inc. | Antibodies against monocyte chemotactic proteins |
| JP4468172B2 (ja) * | 2002-08-19 | 2010-05-26 | アブジェニックス・インコーポレーテッド | 単球走化性タンパク質−１（ｍｃｐ−１）に対する抗体、およびその使用 |
| CN1681926A (zh) * | 2002-09-12 | 2005-10-12 | 财团法人化学及血清疗法研究所 | 人的抗人mcp－1抗体和该抗体的片段 |
| WO2005044200A2 (en) * | 2003-11-05 | 2005-05-19 | Centocor, Inc. | Methods and compositions for treating mcp-1 related pathologies |
| WO2005108431A1 (en) * | 2004-05-04 | 2005-11-17 | University Of Kentucky Research Foundation | Methods and compositions for the treatment of ocular neovascularization |
| GB0412400D0 (en) * | 2004-06-03 | 2004-07-07 | Univ Newcastle | Treatment of inflammatory conditions |
| US8114964B2 (en) * | 2005-05-19 | 2012-02-14 | Centocor, Inc. | Anti-MCP-1 antibodies, compositions, methods and uses |
| TW200716174A (en) * | 2005-05-19 | 2007-05-01 | Centocor Inc | Anti-MCP-1 antibodies, compositions, methods and uses |
| EP2041568A4 (en) * | 2006-06-15 | 2009-08-12 | CCR2 ANTAGONISTS FOR CHRONIC BREATHING REACTIONS IN ORGAN TRANSPLANTATIONS | |
| ES2434039T3 (es) * | 2006-07-24 | 2013-12-13 | Yeda Research And Development Co. Ltd. | Composiciones farmacéuticas que comprenden ccl2 para su uso en el tratamiento de la inflamación |
| US20080076120A1 (en) * | 2006-09-14 | 2008-03-27 | Millennium Pharmaceuticals, Inc. | Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders |
| WO2008060783A2 (en) * | 2006-10-05 | 2008-05-22 | Centocor Ortho Biotech Inc. | Ccr2 antagonists for treatment of fibrosis |
| AU2007337983A1 (en) * | 2006-12-22 | 2008-07-03 | Ablynx N.V. | Anti-chemokine (CCL2, CCL3, CCL5, CXCL11, CXCL12) single-domain antibodies |
| JP2011517548A (ja) * | 2007-06-29 | 2011-06-16 | セントコア・オーソ・バイオテツク・インコーポレーテツド | 抗ｍｃｐ−１抗体、組成物、方法及び使用 |
| WO2009061830A1 (en) * | 2007-11-06 | 2009-05-14 | Massachusetts Eye & Ear Infirmary | Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor |
| JP5685535B2 (ja) | 2008-08-18 | 2015-03-18 | ファイザー インコーポレイティッド | Ｃｃｒ２に対する抗体 |
| CA2734800C (en) | 2008-08-20 | 2021-02-09 | Probiodrug Ag | Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (mcp-1 n1pe) |
| RU2014144463A (ru) * | 2009-06-25 | 2015-06-20 | Фред Хатчинсон Кансэр Рисёч Сентер | Способ измерения адаптивного иммунитета |
| HK1208236A1 (en) | 2012-06-22 | 2016-02-26 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind ccr2 |
| BR112017002980A2 (pt) * | 2014-08-15 | 2017-12-12 | Pixarbio Corp | composição para inibir a inflamação em um indivíduo com um dano na coluna vertebral, método para tratar inflamação em um indivíduo tendo um dano na coluna vertebral e kit para produzir a composição |
| CN104198727A (zh) * | 2014-08-22 | 2014-12-10 | 广西南宁隆吉维特生物科技有限公司 | 人血清ccl2酶联免疫检测试剂盒及其制备和使用方法 |
| EP3050574B1 (en) | 2015-01-28 | 2019-10-09 | Universite De Bordeaux | Use of plerixafor for treating and/or preventing acute exacerbations of chronic obstructive pulmonary disease |
| CN105695495B (zh) * | 2015-12-07 | 2020-02-18 | 中国石油大学(华东) | 一种高活性人趋化因子的制备方法及用途 |
| US20180164221A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| CN108048408B (zh) * | 2018-01-26 | 2020-02-07 | 扬州大学 | 牛单核细胞趋化蛋白-1杂交瘤细胞株、其分泌的单克隆抗体及应用 |
| WO2020106754A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| US20220204608A1 (en) | 2019-04-17 | 2022-06-30 | Hiroshima University | Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination |
| WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| PE20221661A1 (es) * | 2019-12-18 | 2022-10-26 | Hoffmann La Roche | Anticuerpos anti-ccl2 biespecificos |
| CN112358547A (zh) * | 2020-09-30 | 2021-02-12 | 浙江大学 | 抗人cxcl-2单克隆抗体3-d3及其编码基因和应用 |
| CN119684454B (zh) * | 2024-12-25 | 2025-09-12 | 武汉爱博泰克生物科技有限公司 | 针对人mcp-1蛋白的抗体、抗体对和试剂盒及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9019552D0 (en) * | 1990-09-07 | 1990-10-24 | Unilever Plc | Specific binding agents |
| GB9115364D0 (en) * | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| CA2572289A1 (en) * | 2004-06-30 | 2006-08-17 | Centocor, Inc. | Anti-mcp-1 antibodies, compositions, methods and uses |
-
2000
- 2000-06-30 GB GBGB0016138.0A patent/GB0016138D0/en not_active Ceased
-
2001
- 2001-06-28 AR ARP010103086A patent/AR046379A1/es not_active Application Discontinuation
- 2001-06-28 PE PE2001000649A patent/PE20020125A1/es not_active Application Discontinuation
- 2001-06-29 CZ CZ20024256A patent/CZ20024256A3/cs unknown
- 2001-06-29 ES ES01962800T patent/ES2322643T3/es not_active Expired - Lifetime
- 2001-06-29 PL PL359854A patent/PL207133B1/pl not_active IP Right Cessation
- 2001-06-29 CN CNB018120652A patent/CN100486996C/zh not_active Expired - Fee Related
- 2001-06-29 RU RU2003100512/13A patent/RU2314316C2/ru not_active IP Right Cessation
- 2001-06-29 CA CA002412775A patent/CA2412775A1/en not_active Abandoned
- 2001-06-29 AU AU8390301A patent/AU8390301A/xx active Pending
- 2001-06-29 KR KR1020027017405A patent/KR100603899B1/ko not_active Expired - Fee Related
- 2001-06-29 SK SK1812-2002A patent/SK18122002A3/sk unknown
- 2001-06-29 EP EP01962800A patent/EP1299421B1/en not_active Expired - Lifetime
- 2001-06-29 BR BR0112086-7A patent/BR0112086A/pt not_active IP Right Cessation
- 2001-06-29 JP JP2002507891A patent/JP3920215B2/ja not_active Expired - Fee Related
- 2001-06-29 IL IL15372101A patent/IL153721A0/xx unknown
- 2001-06-29 MX MXPA03000201A patent/MXPA03000201A/es active IP Right Grant
- 2001-06-29 WO PCT/EP2001/007468 patent/WO2002002640A2/en not_active Ceased
- 2001-06-29 AU AU2001283903A patent/AU2001283903B2/en not_active Ceased
- 2001-06-29 DE DE60138102T patent/DE60138102D1/de not_active Expired - Lifetime
- 2001-06-29 PT PT01962800T patent/PT1299421E/pt unknown
- 2001-06-29 US US10/312,022 patent/US20040047860A1/en not_active Abandoned
- 2001-06-29 AT AT01962800T patent/ATE426616T1/de not_active IP Right Cessation
- 2001-06-29 HU HU0301477A patent/HUP0301477A3/hu unknown
- 2001-06-29 NZ NZ523195A patent/NZ523195A/en unknown
-
2002
- 2002-12-17 NO NO20026063A patent/NO20026063L/no not_active Application Discontinuation
- 2002-12-24 EC EC2002004402A patent/ECSP024402A/es unknown
-
2003
- 2003-01-08 ZA ZA200300199A patent/ZA200300199B/en unknown
-
2006
- 2006-11-21 JP JP2006314441A patent/JP2007054079A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR046379A1 (es) | Una molecula de enlace de mcp-1 humana, un proceso para dicha produccion, construcciones de adn, un vector de expresion, composiciones farmaceuticas y el uso de dicha molecula de enlace de mcp-1 para la preparacion de un medicamento | |
| AR035581A1 (es) | Anticuerpos para il-1beta humana | |
| BR0207151A (pt) | Moléculas de aglutinação terapêuticas | |
| CY1110033T1 (el) | Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45 | |
| CL2008002923A1 (es) | Anticuerpo monoclonal humano aislado porque se adhiere a mesotelina humana; composicion que comprende dicho anticuerpo; conjugado entre anticuerpo y agente terapeutico; molecula de acido nucleico que codifica el anticuerpo; uso para preparar un medicamento para tratar cancer. | |
| PE20170912A1 (es) | Conjugados de anticuerpo-farmaco | |
| CL2010000790A1 (es) | Anticuerpos monoclonales que se unen a integrina alfa-nu-beta6 (atcc pta-3898) composicion; hibridoma que lo produce; usos para preparar un medicamento para tratar fibrosis, psoriasis, cancer y otros (div.sol.no. 513-03). | |
| PE20011219A1 (es) | ANTICUERPOS PARA IL-1ß HUMANA | |
| CO5280086A1 (es) | Molecula de enlace de cd154, construccion de adn, vector de expresion, composcion y combinacion farmaceutica | |
| PE20110797A1 (es) | Anticuerpos anti mn | |
| PE20060418A1 (es) | Anticuerpos antagonistas de il-17 | |
| BRPI0508716A (pt) | anticorpo monoclonal, processo para produzir o mesmo, composição farmacêutica, e, uso de um anticorpo monoclonal | |
| AR069903A1 (es) | Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer | |
| RU2003100512A (ru) | Антитела к человеческому мср-1 | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| CY1118369T1 (el) | Αντισωματα εναντι cd38 για την θεραπεια πολλαπλου μυελωματος | |
| CO6251370A2 (es) | Una molecula de union cd20 humanizda que comprende un dominio variable de cadena pesada de inmunoglobulina (vh) y un dominio variable de cadena liviana de inmunoglobulina (vl) y metodos de uso de la misma | |
| PE20201255A1 (es) | Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos | |
| PE20050925A1 (es) | Anticuerpo recombinante humanizado anti-interleuquina 10 | |
| BRPI0407233A (pt) | Anticorpo neutralizante, molécula de anticorpo, anticorpo enxertado em cdr, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção da molécula de anticorpo, e, composição farmacêutica | |
| RU2009148597A (ru) | Новые показания к применению при лечении антителами против il-1-бета | |
| PE20221256A1 (es) | Anticuerpos dirigidos a flt3 y uso de los mismos | |
| BRPI0619595B8 (pt) | anticorpo neutralizante, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de um anticorpo, composição farmacêutica, e, uso de um anticorpo neutralizante humanizado | |
| RU2016130108A (ru) | Конъюгаты полипептидного токсина и антитела, соединенных ковалентной связью | |
| PE20241177A1 (es) | Proteinas de union a la mesotelina y usos de las mismas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |